Dr Oliver Van Oekelen talks to ecancer about his study looking at the clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy.
He begins by explaining that the use of BCMA-targeted CAR T therapy has been promising but there are still some question marks over the durability of responses.
Dr Van Oekelen goes on to say that the field of multiple myeloma treatment is moving fast, with the hope that even more treatments will be available in the coming years.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.